Mizuho on Immatics (IMTX): 'BMS Cell Therapy Collaboration Discontinued, but No Material Impact; Stock Attractive Here'

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/15/2026

1. AMAT
2. GLOB
3. SPY
4. RDDT
5. HTFL
6. SNDK
7. WDAY
8. ADYEN:NA
9. DVLT
10. ADYYF

Go back to Mizuho on Immatics (IMTX): 'BMS Cell Therapy Collaboration Discontinued, but No Material Impact; Stock Attractive Here'

Clear Street Starts Immatics (IMTX) at Buy

December 12, 2024 1:17 PM EST

Clear Street analyst Kaveri Pohlman initiates coverage on Immatics (NASDAQ: IMTX) with a Buy rating and a price target of $18.00.

The analyst comments "We are initiating coverage on Immatics with a Buy rating and a $18 PT. With data better than its competitors but... More